Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
Semax is a synthetic ACTH(4–7)-derived heptapeptide extended with Pro-Gly-Pro. Much of its published literature comes from Russian preclinical and regional clinical research.
Key points
- The compound is the sequence Met-Glu-His-Phe-Pro-Gly-Pro, designed from an ACTH fragment without the parent hormone’s full sequence.
- Evidence from cells, animals and humans must be interpreted separately.
- Not authorised by the MHRA as a medicine; regulatory status differs internationally.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
Semax is a synthetic ACTH(4–7)-derived heptapeptide extended with Pro-Gly-Pro. Much of its published literature comes from Russian preclinical and regional clinical research. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
Experimental studies report changes in neurotrophin-related, inflammatory and gene-expression pathways after cerebral-ischaemia models. These findings do not establish a cognitive or neurological benefit in general populations.
What does the current evidence show?
- Rat ischaemia studies report changes in immune-response and neurotrophin-related gene expression.
- Some regional clinical reports concern stroke settings, but independent replication and internationally accessible trial detail are limited.
- Robust, contemporary, multicentre trials supporting common online nootropic claims were not identified.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- A large proportion of the accessible evidence is preclinical.
- Clinical literature is geographically concentrated and often difficult to appraise in full.
- Stroke-model findings should not be generalised to enhancement claims in healthy people.
Regulatory and safety context
Not authorised by the MHRA as a medicine; regulatory status differs internationally. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
- Ischaemia gene-expression study — PubMed
- Rat proteomic study — PubMed
- Semax literature search — PubMed
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.